Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis b in patients with decompensated cirrhosis from a third-party us payer perspective
Naoky Tsai, Lennox Jeffers, Lael Cragin, Sonja Sorensen, Wenqing Su, Lisa Rosenblatt, Hong Tang, Tony Hebden, Timothy Juday
Fingerprint
Dive into the research topics of 'Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis b in patients with decompensated cirrhosis from a third-party us payer perspective'. Together they form a unique fingerprint.